Till startsida
Webbkarta
Till innehåll Läs mer om hur kakor används på gu.se

Metabolic effects of Lactobacillus reuteri DSM 17938 in people with type 2 diabetes: A randomized controlled trial

Artikel i vetenskaplig tidskrift
Författare Reza Mobini
Valentina Tremaroli
Marcus Ståhlman
F. Karlsson
Max Levin
Maria Ljungberg
Maja Sohlin
Helene Berteus Forslund
Rosie Perkins
Fredrik Bäckhed
Per-Anders Jansson
Publicerad i Diabetes Obesity & Metabolism
Volym 19
Nummer/häfte 4
Sidor 579-589
ISSN 1462-8902
Publiceringsår 2017
Publicerad vid Wallenberglaboratoriet
Institutionen för kliniska vetenskaper, sektionen för onkologi, radiofysik, radiologi och urologi, Avdelningen för radiofysik
Institutionen för medicin, avdelningen för invärtesmedicin och klinisk nutrition
Institutionen för medicin, avdelningen för molekylär och klinisk medicin
Sidor 579-589
Språk English
Länkar doi.org/10.1111/dom.12861
Ämnesord bile acids, gut microbiota, insulin sensitivity, Lactobacillus reuteri DSM 17938, probiotic, controlled clinical-trial, gut microbiota, glucose-homeostasis, insulin-resistance, lipid profile, obesity, probiotics, metaanalysis, management, secretion, Endocrinology & Metabolism
Ämneskategorier Endokrinologi och diabetes

Sammanfattning

Aims: To investigate the metabolic effects of 12-week oral supplementation with Lactobacillus reuteri DSM 17938 in patients with type 2 diabetes on insulin therapy. Materials and methods: In a double-blind trial, we randomized 46 people with type 2 diabetes to placebo or a low (10(8) CFU/d) or high dose (10(10) CFU/d) of L. reuteri DSM 17938 for 12 weeks. The primary endpoint was the effect of supplementation on glycated haemoglobin (HbA1c). Secondary endpoints were insulin sensitivity (assessed by glucose clamp), liver fat content, body composition, body fat distribution, faecal microbiota composition and serum bile acids. Results: Supplementation with L. reuteri DSM 17938 for 12 weeks did not affect HbA1c, liver steatosis, adiposity or microbiota composition. Participants who received the highest dose of L. reuteri exhibited increases in insulin sensitivity index (ISI) and serum levels of the secondary bile acid deoxycholic acid (DCA) compared with baseline, but these differences were not significant in the between-group analyses. Post hoc analysis showed that participants who responded with increased ISI after L. reuteri supplementation had higher microbial diversity at baseline, and increased serum levels of DCA after supplementation. In addition, increases in DCA levels correlated with improvement in insulin sensitivity in the probiotic recipients. Conclusions: Intake of L. reuteri DSM 17938 for 12 weeks did not affect HbA1c in people with type 2 diabetes on insulin therapy; however, L. reuteri improved insulin sensitivity in a subset of participants and we propose that high diversity of the gut microbiota at baseline may be important.

Sidansvarig: Webbredaktion|Sidan uppdaterades: 2012-09-11
Dela:

På Göteborgs universitet använder vi kakor (cookies) för att webbplatsen ska fungera på ett bra sätt för dig. Genom att surfa vidare godkänner du att vi använder kakor.  Vad är kakor?